Cargando…
SAT-532 Bisphosphonates Prevent Bone Loss Associated with Denosumab Treatment Discontinuation
Denosumab (DMAb) is a soluble inhibitor of RANKL and, therefore, does not incorporate into the bone matrix. Consistently, DMAb discontinuation is associated with the reversal of the effects attained with treatment. Concerns have been raised regarding possible increased vertebral fragility following...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Endocrine Society
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552094/ http://dx.doi.org/10.1210/js.2019-SAT-532 |